PT  - JOURNAL ARTICLE
AU  - Toffoli, M
AU  - Chohan, H
AU  - Mullin, S
AU  - Jesuthasan, A
AU  - Yalkic, S
AU  - Koletsi, S
AU  - Menozzi, E
AU  - Rahall, S
AU  - Limbachiya, N
AU  - Loefflad, N
AU  - Higgins, A
AU  - Bestwick, J
AU  - Lucas-Del-Pozo, S
AU  - Fierli, F
AU  - Farbos, A
AU  - Mezabrovschi, R
AU  - Lee-Yin, C
AU  - Schrag, A
AU  - Moreno-Martinez, D
AU  - Hughes, D
AU  - Noyce, A
AU  - Colclough, K
AU  - Jeffries, AR
AU  - Proukakis, C
AU  - Schapira, AHV
TI  - Phenotypic effect of <em>GBA1</em> variants in individuals with and without Parkinson disease: the RAPSODI study
AID  - 10.1101/2023.07.25.23291637
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.07.25.23291637
4099  - http://medrxiv.org/content/early/2023/07/27/2023.07.25.23291637.short
4100  - http://medrxiv.org/content/early/2023/07/27/2023.07.25.23291637.full
AB  - Background Variants in the GBA1 gene cause the lysosomal storage disorder Gaucher disease (GD). They are also risk factors for Parkinson disease (PD), and modify the expression of the PD phenotype.The penetrance of GBA1 variants in PD is incomplete, and the ability to determine who amongst GBA1 variant carriers are at higher risk of developing PD, would represent an advantage for prognostic and trial design purposes.Objectives To compare the motor and non-motor phenotype of GBA1 carriers and non-carriers.Methods We present the cross-sectional results of the baseline assessment from the RAPSODI study, an online assessment tool for PD patients and GBA1 variant carriers. The assessment includes clinically validated questionnaires, a tap-test, the University of Pennsyllvania Smell Identification Test and cognitive tests. Additional, homogeneous data from the PREDICT-PD cohort were included.Results A total of 379 participants completed all parts of the RAPSODI assessment (89 GBA1-negative controls, 169 GBA1-negative PD, 47 GBA1-positive PD, 47 non-affected GBA1 carriers, 27 GD). Eightysix participants were were recruited through PREDICT-PD (43 non-affected GBA1 carriers and 43 GBA1-negative controls). GBA1-positive PD showed worse performance in visual cognitive tasks and olfaction compared to GBA1-negative PD patients. No differences were detected between non-affected GBA1 carriers carriers and GBA1-negative controls. No phenotypic differences were observed between any of the non-PD groups.Conclusions Our results support previous evidence that GBA1-positive PD has a specific phenotype with more severe non-motor symptoms. However, we did not reproduce previous findings of more frequent prodromal PD signs in non-affected GBA1 carriers.Competing Interest StatementToffoli M Employee of NHS and UCL Chohan H Employee of UCL Mullin S Employee of NHS Jesuthasan A Nothing to disclose Yalkic S Employee of UCL Koletsi S Employee of UCL Menozzi E was supported by a Royal Free Charity Fellowship Rahall S Nothing to disclose Limbachiya N Nothing to disclose Loefflad N Employee of UCL Higgins A Nothing to disclose Bestwick J Nothing to disclose Lucas-Del-Pozo S was supported by a UCL fellowship. Fierli F Employee of UCL Farbos A Employee of University of Exeter Mezabrovschi R Employee of UCL Lee-Yin C Nothing to disclose Schrag A Nothing to disclose Moreno-Martinez D received travel grants from Sanofi, Takeda and Amicus. Hughes D received honoraria for speaking and consulting and travel arrangements from Sanofi and Takeda Noyce A grants from Parkinson UK, Barts Charity, Cure Parkinson, National Institute for Health and Care Research, Innovate UK, Virginia Keiley benefaction, Solvemed, the Medical College of Saint Bartholomew Hospital Trust, Alchemab, Aligning Science Across Parkinson Global Parkinson Genetics Program (ASAP-GP2) and the Michael J Fox Foundation. Prof Noyce reports consultancy and personal fees from AstraZeneca, AbbVie, Profile, Roche, Biogen, UCB, Bial, Charco Neurotech, uMedeor, Alchemab, Sosei Heptares and Britannia, outside the submitted work. Prof Noyce is an Associate Editor for the Journal of Parkinson Disease Colclough K Employee of NHS Jeffries AR Employee of University of Exeter Proukakis C Employee of NHS and UCL. Schapira AHV Employee of NHS and UCL. Medical Research Council, Michael J. Fox Foundation (MJFF), Aligning Science Across Parkinson, and Cure Parkinson (research support); AvroBio, Auxilius, Coave, Destin, Enterin, Escape Bio, Genilac, and Sanofi (consulting fees); and Prada Foundation (speaking fees).Funding StatementThis research was funded in part by Aligning Science Across Parkinson [ASAP-000420] through the Michael J. Fox Foundation for Parkinson Research (MJFF). For the purpose of open access, the author has applied a CC BY public copyright license to all Author Accepted Manuscripts arising from this submission. The work was supported by the EU Joint Programme, Neurodegenerative Disease Research (JPND) project (GBA-PaCTS, 01ED2005B) and MR/T046007/1. The PREDICT-PD study was funded by Parkinson UK. This research was funded in part by Aligning Science Across Parkinson [ASAP-000420] through the Michael J. Fox Foundation for Parkinson ResearchAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants gave informed consent to be included in the study. The work was approved by the London, Queen Square Research Ethics Committee (REC reference: 15/LO/1155). We confirm that we have read the Journal position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. Ethical approval for the PREDICT-PD study was grant by Central London Research Ethics Committee 3 (reference number 10/H0716/85).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesParticipant level data are reported as supplementary material in the file named “participant-level data”.All other data produced in the present study are available upon reasonable request to the authors.